[1]苏 成,李 斌,王可为△.术前新辅助化疗对三阴性乳腺癌患者血清Ki67、PDL1表达的影响*[J].陕西医学杂志,2019,(12):1605-1607，1611.
　SU Cheng,LI Bin,WANG Kewei..Effects of preoperative neoadjuvant chemotherapy on serum Ki67 and PDL1 expression in patients with triple negative breast cancer[J].,2019,(12):1605-1607，1611.
点击复制

术前新辅助化疗对三阴性乳腺癌患者血清Ki67、PDL1表达的影响*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2019年12期
页码:
1605-1607，1611
栏目:
临床研究
出版日期:
2019-12-05

文章信息/Info

Title:
Effects of preoperative neoadjuvant chemotherapy on serum Ki67 and PDL1 expression in patients with triple negative breast cancer
文章编号:
DOI:10.3969/j.issn.10007377.2019.12.007
作者:
苏 成1; 李 斌1; 王可为2△
1西安医学院附属宝鸡医院普外胸外科(宝鸡 721006);2西安医学院附属宝鸡医院肿瘤内科(宝鸡 721006)
Author(s):
SU Cheng; LI Bin; WANG Kewei.
Department of General Surgery,Affiliated Baoji Hospital of Xi'an Medical University（Baoji 721006）
关键词:
新辅助化疗; 三阴性乳腺癌; 副反应; 细胞核增殖抗原; 程序性死亡受体配体1; 免疫功能; 生存时间
Keywords:
Key words Neoadjuvant chemotherapy; Triple negative breast cancer; Side reaction; Ki67; Programmed cell deathLigand 1; Immune function; Survival time
分类号:
R737.9
文献标志码:
A
摘要:
摘 要 目的：探讨术前新辅助化疗对三阴性乳腺癌患者血清Ki67、程序性死亡受体配体1(PDL1)表达的影响。方法：选择三阴性乳腺癌患者96例，根据随机数字表法分为观察组与对照组各48例。对照组给予常规乳腺癌根治手术及术后化疗治疗，观察组在对照组治疗的基础上给予术前新辅助化疗。检测并分析两组血清Ki67、PDL1表达变化情况。结果：所有患者均顺利完成根治手术治疗，两组治疗期间的不良反应主要为骨髓抑制、恶心呕吐、手足综合征、肝肾功能异常等，对比差异无统计学意义(P＞005)。两组治疗后1个月的血清Ki67、PDL1值显著低于治疗前(P＜005)，观察组显著低于对照组(P＜005)。两组治疗后1个月的IgM与IgA值均显著高于治疗前(P＜005)，观察组显著高于对照组(P＜005)。观察组总生存时间、无进展生存时间显著长于对照组(P＜005)。结论：术前新辅助化疗在三阴性乳腺癌患者的应用能抑制血清Ki67、PDL1的表达，改善机体的免疫功能，且不增加不良反应的发生率，可显著延长患者的生存时间。
Abstract:
Abstract Objective:To investigate the effects of preoperative neoadjuvant chemotherapy on the expression of serum Ki67 and programmed cell deathLigand 1(PDL1) in triplenegative breast cancer patientsMethods:96 patients with triplenegative breast cancer were equally divided into the observation group and control group accorded to the random number table methodThe control group were received conventional radical mastectomy,and the observation group were received preoperative neoadjuvant chemotherapy on the basis of the control groupThe expressions of ki67 and pdl1 in serum of the two groups were detected and postoperative chemotherapyResults:All patients underwent radical surgery,the adverse reaction of the two groups were main of myelosuppression,nausea and vomiting,handfoot syndrome,and liver and kidney dysfunction,and compared he difference were not statistically significant (P＞005)The serum Ki67 and PDL1 values of the two groups after treatment were significantly lower than those before treatment (P＜005),and the observation group were also significantly lower than the control group (P＜005)The IgM and IgA values of the two groups after treatment were significantly higher than those before treatment (P＜005),and the observation group were also significantly higher than the control group (P＜005)The overall survival time and progressionfree survival time of the observation group were significantly longer than those of the control group (P＜005)Conclusion:The application of preoperative neoadjuvant chemotherapy in patients with triplenegative breast cancer can inhibit the expression of serum Ki67 and PDL1,improve the immune function of the body,dncrease the incidence of adverse reaction,and prolong the survival time of patients

参考文献/References:

[1] 中国乳腺癌新辅助治疗专家组中国乳腺癌新辅助治疗专家共识(2019年版)[J] .中国癌症杂志,2019,29(5):390400.
[2] 薛文武,谭婷婷中医辨证治疗乳腺癌疗效及对患者癌症指标的影响研究[J] .陕西中医,2018,39(3):388340.
[3] 杨迎旭,金 焰,任中海,等乳腺癌组织中乳腺癌耐药蛋白的表达与新辅助化疗疗效的相关性[J] .中国老年学杂志,2019,39(4):806808.
[4] 王欣冉,张建国炎性乳腺癌的诊断与治疗进展[J] .中国现代普通外科进展,2019,22(4):308311.
[5] 白晓蓉,高 晨,杨碎胜Ki67表达强度对局部晚期乳腺癌新辅助化疗疗效预测的研究[J] .中国现代药物应用,2019,13(10):3839.
[6] 张 凯,杨天瑶,吕振晔,等白蛋白紫杉醇联合表柔比星和环磷酰胺治疗乳腺癌的临床研究[J] .中国临床药理学杂志,2019,35(5):428430,434.
[7] 朱文静,梁 秋新辅助化疗腋窝淋巴结临床完全缓解乳腺癌患者前哨淋巴结活检的可行性分析[J] .中国医师杂志,2019,21(1):5963.
[8] 李 帅,王淑莲,宋永文,等初诊同侧锁骨上淋巴结转移乳腺癌综合治疗疗效[J] .中华放射肿瘤学杂志,2019,28(1):1722.
[9] Fukuoka E,Yamashita K,Tanaka T,et al.Neoadjuvant chemotherapy increases PDL1 expression and CD8(+) tumorinfiltrating lymphocytes in esophageal squamous cell carcinoma[J] .Anticancer Res,2019,39(8):45394548.
[10] 潘力敏,谷元廷,王 芳,等乳腺癌新辅助化疗病理完全缓解的影响因素[J] .河南医学研究,2019,28(4):597599.
[11] 丁小崇新辅助化疗方案联合保乳手术治疗乳腺癌的临床疗效及对患者免疫功能的影响[J] .实用癌症杂志,2019,34(2):328330.
[12] 李 旭,安改丽,黄尚科,等阿帕替尼对三阴性乳腺癌MDAMB231细胞抑制作用体外研究[J] .陕西医学杂志,2016,45(11):14451447.
[13] 陈 馨,张 薇,张伟杰,等肿瘤相关巨噬细胞CD68蛋白与乳腺癌临床病理特征对新辅助化疗疗效和预后的影响[J] .临床与病理杂志,2019,39(3):535542.
[14] 谢轶莲ECTX与ECTO方案术前新辅助化疗在三阴性乳腺癌治疗中的疗效观察[J] .现代实用医学,2019,31(4):467469.
[15] Yu J,Lee SH,Jeung TS,et al.Expression of vascular endothelial growth factor as a predictor of complete response for preoperative chemoradiotherapy in rectal cancer[J] .Medicine (Baltimore),2019,98(26):e16190.
[16] Yu Y,Ma X,Zhang Y,et al.Changes in expression of multiple checkpoint molecules and infiltration of tumor immune cells after neoadjuvant chemotherapy in gastric cancer[J] .J Cancer,2019,10(12):27542763.
[17] 欧阳学哲,刘 慧雄激素受体在三阴性乳腺癌中的表达及预后意义[J] .临床外科杂志,2019,27(3):227230

相似文献/References:

[1]韩丕华,宋张骏△,杨晓民,等.乳腺超声造影联合细针穿刺定位活检在判定乳腺癌新辅助化疗后腋窝淋巴结性质中的临床研究*[J].陕西医学杂志,2019,(7):842.
　HAN Pihua,SONG Zhangjun,YANG Xiaomin,et al.Application of breast contrast-enhanced ultrasonography combined with fine needle aspiration biopsy in determining the axillary lymph node properties after neoadjuvant chemotherapy for breast cancer[J].,2019,(12):842.
[2]祝景伟,佟经伟,许培权△.Hippo信号通路中TAZ、YAP在三阴性乳腺癌中的表达及意义[J].陕西医学杂志,2020,49(8):940.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.007]
　ZHU Jingwei,TONG Jingwei,XU Peiquan..Expression and significance of TAZ and YAP in Hippo signaling pathway in triple negative breast cancer[J].,2020,49(12):940.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.007]
[3]马少君,刘延梅△,康晓丽,等.三阴性乳腺癌雄激素受体表达与X线和超声影像特征关系研究*[J].陕西医学杂志,2020,49(12):1584.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.012]
[4]李秀华,唐冬梅,朱丽萍,等.三阴性乳腺癌临床病理特征与基因分型研究[J].陕西医学杂志,2021,50(8):1015.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.028]
　LI Xiuhua,TANG Dongmei,ZHU Liping,et al.Clinicopathological features and genotyping of triple negative breast cancer[J].,2021,50(12):1015.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.028]
[5]徐英杰,李 巍.三阴性乳腺癌早期患者雄激素受体、Ki67、p53、表皮生长因子受体表达水平及其与临床病理特征关系研究[J].陕西医学杂志,2021,50(12):1594.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.032]
　XU Yingjie,LI Wei.Expression levels of androgen receptor,Ki67,p53,epidermal growth factor receptor and their relationship with clinicopathological characteristics in early stage triple-negative breast cancer patients[J].,2021,50(12):1594.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.032]

备注/Memo

备注/Memo:
*国家自然科学基金资助项目（81873421）
更新日期/Last Update: 2019-12-19